Structure-guided design of a high-affinity platelet integrin α IIbβ 3 receptor antagonist that disrupts Mg 2+ binding to the MIDAS

Science Translational Medicine

Volumn 4, Issue 125, 2012, Pages

  Zhu, Jieqing ^a,b   Choi, Won Seok ^c   McCoy, Joshua G ^d   Negri, Ana ^e   Zhu, Jianghai ^a   Naini, Sarasija ^c   Li, Jihong ^c   Shen, Min ^d   Huang, Wenwei ^d   Bougie, Daniel ^b   Rasmussen, Mark ^b   Aster, Richard ^b   Thomas, Craig J ^d   Filizola, Marta ^e   Springer, Timothy A ^a   Coller, Barry S ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [3 [5 OXO 7 (PIPERAZIN 1 YL) 5H [1,3,4]THIADIAZOLO[3,2A]PYRIMIDIN 2 YL]PHENYL]ACETAMIDE; ALPHA2B BETA3 INTEGRIN; ANTICOAGULANT AGENT; CALCIUM ION; COLLAGEN; EPITOPE; EPTIFIBATIDE; ETARACIZUMAB; GLUTAMIC ACID; HEMATOLOGIC AGENT; INTEGRIN; MAGNESIUM ION; MONOCLONAL ANTIBODY; RUC 1; RUC 2; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN; ANTITHROMBOCYTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; FIBRINOGEN; FIBRINOGEN RECEPTOR; MAGNESIUM; OLIGOPEPTIDE;

ANIMAL CELL; ANTICOAGULATION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; EMBRYO; GEL CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; LIGHT SCATTERING; METAL BINDING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL ADHESION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; THROMBOCYTE;

ANIMALS; BINDING SITES; BLOOD PLATELETS; CELL ADHESION; COLLAGEN; CRYSTALLOGRAPHY, X-RAY; FIBRINOGEN; HUMANS; MAGNESIUM; MICE; MICROSCOPY, ELECTRON; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; RATS; VITRONECTIN;

EID: 84863375270     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003576     Document Type: Article

References (54)

1. R. O. Hynes, Integrins: Bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
2. B. H. Luo, C. V. Carman, T. A. Springer, Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619-647 (2007).
3. K. Ley, C. Laudanna, M. I. Cybulsky, S. Nourshargh, Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007).
4. W. Zou, S. L. Teitelbaum, Integrins, growth factors, and the osteoclast cytoskeleton. Ann. N. Y. Acad. Sci. 1192, 27-31 (2010).
5. P. T. Caswell, S. Vadrevu, J. C. Norman, Integrins: Masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol. 10, 843-853 (2009).
6. X. Lu, D. Lu, M. Scully, V. Kakkar, The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect. Medicin. Chem. 2, 57-73 (2008).
7. B. S. Coller, S. J. Shattil, The GPIIb/IIIa (integrin αIIbß3) odyssey: A technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112, 3011-3025 (2008).
8. X. Bosch, J. Marrugat, J. Sanchis, Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst. Rev. 9, CD002130 (2010).
9. D. W. Bougie, P. R. Wilker, E. D. Wuitschick, B. R. Curtis, M. Malik, S. Levine, R. N. Lind, J. Pereira, R. H. Aster, Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100, 2071-2076 (2002).
10. 3 cytoplasmic domain. J. Clin. Invest. 119, 504-511 (2009).
11. D. P. Chew, D. L. Bhatt, E. J. Topol, Oral glycoprotein IIb/IIIa inhibitors: Why don't they work? Am. J. Cardiovasc. Drugs 1, 421-428 (2001).
12. D. Cox, Oral GPIIb/IIIa antagonists: What went wrong? Curr. Pharm. Des. 10, 1587-1596 (2004).
13. B. M. Scirica, C. P. Cannon, R. Cooper, R. H. Aster, J. Brassard, C. H. McCabe, A. Charlesworth, A. M. Skene, E. Braunwald, Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J. Thromb. Thrombolysis 22, 95-102 (2006).
14. L. K. Jennings, J. H. Haga, S. M. Slack, Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb. Haemost. 84, 1095-1102 (2000).
15. W. C. Kouns, D. Kirchhofer, P. Hadváry, A. Edenhofer, T. Weller, G. Pfenninger, H. R. Baumgartner, L. K. Jennings, B. Steiner, Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 80, 2539-2547 (1992).
16. 3) inhibitors. Blood 92, 3240-3249 (1998).
17. S. Epelman, D. Nair, R. Downey, M. Militello, A. T. Askari, Eptifibatide-induced thrombocytopenia and thrombosis. J. Thromb. Thrombolysis 22, 151-154 (2006).
18. D. P. Chew, D. L. Bhatt, S. Sapp, E. J. Topol, Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 103, 201-206 (2001).
19. D. Seiffert, A. M. Stern, W. Ebling, R. J. Rossi, Y. C. Barrett, R. Wynn, G. F. Hollis, B. He, C. J. Kieras, D. L. Pedicord, D. A. Cromley, T. A. Hua, R. B. Stein, R. N. Daly, A. Sferruzza, H. J. Pieniaszek, J. T. Billheimer, Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 101, 58-63 (2003).
20. 3 (GPIIb/IIIa) antagonists. Arterioscler. Thromb. Vasc. Biol. 27, e9-e15 (2007).
21. J. Zhu, B. H. Luo, T. Xiao, C. Zhang, N. Nishida, T. A. Springer, Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol. Cell 32, 849-861 (2008).
22. 3. J. Cell Biol. 182, 791-800 (2008).
23. T. Xiao, J. Takagi, B. S. Coller, J. H. Wang, T. A. Springer, Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432, 59-67 (2004).
24. 1 in complex with fibronectin. EMBO J. 22, 4607-4615 (2003).
25. A. K. Hassan, J. W. Jukema, A. van der Laarse, H. Hasan-Ali, R. Wolterbeek, F. van der Kley, F. Spano, D. E. Atsma, M. J. Schalij, Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: Prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention 4, 662-668 (2009).
26. G. De Luca, C. M. Gibson, F. Bellandi, S. Murphy, M. Maioli, M. Noc, U. Zeymer, D. Dudek, H. R. Arntz, S. Zorman, H. M. Gabriel, A. Emre, D. Cutlip, G. Biondi-Zoccai, T. Rakowski, M. Gyongyosi, P. Marino, K. Huber, A. W. van't Hof, Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart 94, 1548-1558 (2008).
27. G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, J. M. Boulenc, M. C. Morice, L. Maillard, M. Pansiéri, R. Choussat, P. Pinton; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long- Term Follow-up, Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344, 1895-1903 (2001).
28. R. Blue, M. Murcia, C. Karan, M. Jirousková, B. S. Coller, Application of high-throughput screening to identify a novel αIIβ-specific small-molecule inhibitor of αIIbß3-mediated platelet interaction with fibrinogen. Blood 111, 1248-1256 (2008).
29. R. Blue, M. A. Kowalska, J. Hirsch, M. Murcia, C. A. Janczak, A. Harrington, M. Jirouskova, J. Li, R. Fuentes, M. A. Thornton, M. Filizola, M. Poncz, B. S. Coller, Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel αIIb-specific αIIbß3 antagonist. Blood 114, 195-201 (2009).
30. 3-specific antagonist that does not induce opening. Blood 116, 5050-5059 (2010).
31. B. S. Coller, J. H. Beer, L. E. Scudder, M. H. Steinberg, Collagen-platelet interactions: Evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 74, 182-192 (1989).
32. 3 subunit. J. Biol. Chem. 270, 11947-11954 (1995).
33. A. L. Frelinger III, I. Cohen, E. F. Plow, M. A. Smith, J. Roberts, S. C. Lam, M. H. Ginsberg, Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. 265, 6346-6352 (1990).
34. P. J. Shadle, M. H. Ginsberg, E. F. Plow, S. H. Barondes, Platelet-collagen adhesion: Inhibition by a monoclonal antibody that binds glycoprotein IIb. J. Cell Biol. 99, 2056-2060 (1984).
35. F. Ye, G. Hu, D. Taylor, B. Ratnikov, A. A. Bobkov, M. A. McLean, S. G. Sligar, K. A. Taylor, M. H. Ginsberg, Recreation of the terminal events in physiological integrin activation. J. Cell Biol. 188, 157-173 (2010).
36. 3 (platelet GPIIb-IIIa). Cell 65, 409-416 (1991).
37. R. R. Hantgan, M. C. Stahle, Integrin priming dynamics: Mechanisms of integrin antagonistpromoted αIIbß3:PAC-1 molecular recognition. Biochemistry 48, 8355-8365 (2009).
38. 3 priming and clustering by orally active and intravenous integrin antagonists. J. Thromb. Haemost. 5, 542-550 (2007).
39. 2+ signaling. Blood 92, 3675-3683 (1998).
40. R. R. Hantgan, M. C. Stahle, S. T. Lord, Dynamic regulation of fibrinogen: Integrin αIIbß3 binding. Biochemistry 49, 9217-9225 (2010).
41. A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, A. D. Michelson, Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 104, 1374-1379 (2001).
42. E. K. Baker, E. C. Tozer, M. Pfaff, S. J. Shattil, J. C. Loftus, M. H. Ginsberg, A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro. Proc. Natl. Acad. Sci. U.S.A. 94, 1973-1978 (1997).
43. 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 249, 915-918 (1990).
44. J. P. Xiong, T. Stehle, B. Diefenbach, R. Zhang, R. Dunker, D. L. Scott, A. Joachimiak, S. L. Goodman, M. A. Arnaout, Crystal structure of the extracellular segment of integrin αVβ3. Science 294, 339-345 (2001).
45. 3 A-domain. J. Biol. Chem. 281, 23034-23041 (2006).
46. V. L. Roger, A. S. Go, D. M. Lloyd-Jones, R. J. Adams, J. D. Berry, T. M. Brown, M. R. Carnethon, S. Dai, G. de Simone, E. S. Ford, C. S. Fox, H. J. Fullerton, C. Gillespie, K. J. Greenlund, S. M. Hailpern, J. A. Heit, P. M. Ho, V. J. Howard, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, D. M. Makuc, G. M. Marcus, A. Marelli, D. B. Matchar, M. M. McDermott, J. B. Meigs, C. S. Moy, D. Mozaffarian, M. E. Mussolino, G. Nichol, N. P. Paynter, W. D. Rosamond, P. D. Sorlie, R. S. Stafford, T. N. Turan, M. B. Turner, N. D. Wong, J. Wylie-Rosett; American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics - 2011 update: A report from the American Heart Association. Circulation 123, e18-e209 (2011).
47. H. K. Gold, H. D. Garabedian, R. E. Dinsmore, L. J. Guerrero, J. E. Cigarroa, I. F. Palacios, R. C. Leinbach, Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 95, 1755-1759 (1997).
48. Z. Siudak, T. Rakowski, A. Dziewierz, M. Janzon, R. Birkemeyer, J. Stefaniak, Ł. Partyka, K. Zmudka, D. Dudek, Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol. Pol. 68, 539-543 (2010).
49. G. De Luca, Glycoprotein IIb-IIIa inhibitors. Cardiovasc. Ther. 10.1111/j.1755-5922.2011.00293.x (2011).
50. A. K. Hassan, S. S. Liem, F. van der Kley, S. C. Bergheanu, R. Wolterbeek, J. Bosch, M. Bootsma, K. Zeppenfeld, A. van der Laarse, D. E. Atsma, J. W. Jukema, M. J. Schalij, In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: Results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc. Interv. 74, 335-343 (2009).
51. J. Chen, K. Tan, H. Zhou, H. F. Lo, D. T. Roux, R. C. Liddington, T. G. Diacovo, Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat. Biotechnol. 26, 114-119 (2008).
52. J. Magallon, J. Chen, L. Rabbani, G. Dangas, J. Yang, J. Bussel, T. Diacovo, Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents. Circulation 123, 319-326 (2011).
53. T. K. Ritchie, Y. V. Grinkova, T. H. Bayburt, I. G. Denisov, J. K. Zolnerciks, W. M. Atkins, S. G. Sligar, Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Methods Enzymol. 464, 211-231 (2009).
54. T. H. Bayburt, S. G. Sligar, Membrane protein assembly into nanodiscs. FEBS Lett. 584, 1721-1727 (2010).